Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study

Table 1 Baseline characteristics of patients with diabetes and their matched general population comparison cohort

	Diabetes patients (n = 5734)		General population (n = 28,670)
	N	%	N	%
Male sex	2997	52.3	14,985	52.3
Median age (IQR)	62 years (53-70)		62 years (53-70)
Family history of ischemic heart disease^a
Yes	2058	35.9	–	–
Missing	670	11.7	–	–
Smoking^a
Active	1070	18.7	–	–
Former	2024	35.3	–	–
Never	2008	35.0	–	–
Missing	632	11.0	–	–
CAG procedural indication^a
STEMI	112	2.0	–	–
NSTEMI	259	4.5	–	–
Unstable AP	190	3.3	–	–
Stable AP	2666	46.5	–	–
Arrhythmia	228	4.0	–	–
Valvular disease	665	11.6	–	–
Cardiomyopathy	613	10.7	–	–
Other	899	15.7	–	–
Missing	102	1.8	–	–
Comorbidity
Diabetes	5734	100.0	2041	7.1
Chronic pulmonary disease	626	10.9	1123	3.9
Hypertension	3362	58.6	3110	10.8
Peripheral artery disease	214	3.7	456	1.6
Heart failure	991	17.3	262	0.9
Atrial fibrillation	1070	18.7	979	3.4
Ischemic stroke	201	3.5	285	1.0
Hemorrhagic stroke	12	0.2	69	0.2
MI < 30 days after inclusion	2	0.0	6	0.0
Comedication
Aspirin	3535	61.6	3455	12.1
ADP-inhibitors	261	4.6	286	1.0
Vitamin K-antagonists	909	15.9	830	2.9
DOAC	182	3.2	148	0.5
Statin	4140	72.2	5423	18.9
Beta-blocker	3118	54.4	3227	11.3
ACE-inhibitor	2659	46.4	3832	13.4
ARB	1698	29.6	2870	10.0
Thiazide	1209	21.1	2879	10.0
Calcium-blocker	2050	35.8	3669	12.8
Insulin	1631	28.4	568	2.0
Non-insulin anti-diabetes agents	3658	63.8	1484	5.2

ACE angiotensin converting enzyme, ADP adenosine diphosphate, AP angina pectoris, ARB angiotensin-II receptor blocker, CAG coronary angiography, DOAC direct oral anti-coagulant, MI myocardial infarction, NSTEMI non ST-elevation myocardial infarction, SD standard deviation, STEMI ST-elevation myocardial infarction
^aData provide by the Western Denmark Heart Registry. Unavailable for the general population